Blog Post
Refining the molecular blueprint of in vivo CAR-T cell therapies
In vivo CAR T-cell therapies are on the rise. However, the move in vivo brings additional biological and manufacturing complications to be addressed at the molecular level. The degree of engineering and collaboration required to bring these products to market demands solid digital infrastructure, including robust plasmid design software and collaborative project management tools.











